In the clinical trial KEYNOTE-58, pembrolizumab (programmed cell death-1(PD-1) monoclonal antibody) was used to treat advanced cervical cancer, and the overall response rate (ORR) was 12.2% [15]. The gene discussed is PDCD1; the disease is cervical cancer.